Meeder Asset Management Inc. raised its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 9,017.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,194 shares of the biotechnology company’s stock after buying an additional 4,148 shares during the quarter. Meeder Asset Management Inc.’s holdings in Arrowhead Pharmaceuticals were worth $278,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its position in shares of Arrowhead Pharmaceuticals by 64.3% in the fourth quarter. JPMorgan Chase & Co. now owns 2,409,631 shares of the biotechnology company’s stock worth $184,891,000 after acquiring an additional 943,012 shares during the last quarter. Norges Bank acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $65,894,000. Western Financial Corporation purchased a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at $62,945,000. Bamco Inc. NY increased its holdings in shares of Arrowhead Pharmaceuticals by 78.9% during the 4th quarter. Bamco Inc. NY now owns 664,637 shares of the biotechnology company’s stock worth $50,998,000 after buying an additional 293,216 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $12,179,000. 65.52% of the stock is owned by institutional investors.
A number of equities research analysts have issued reports on the company. B. Riley boosted their price target on Arrowhead Pharmaceuticals from $98.00 to $106.00 and gave the company a “buy” rating in a research report on Monday, February 8th. Citigroup increased their target price on shares of Arrowhead Pharmaceuticals from $90.00 to $110.00 in a research report on Monday, February 8th. Piper Sandler lifted their price target on shares of Arrowhead Pharmaceuticals from $90.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday, February 5th. HC Wainwright increased their price objective on shares of Arrowhead Pharmaceuticals from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, February 5th. Finally, Chardan Capital lifted their target price on shares of Arrowhead Pharmaceuticals from $81.00 to $97.00 and gave the company a “buy” rating in a report on Friday, February 5th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $87.58.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Monday, May 3rd. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.17). Arrowhead Pharmaceuticals had a negative net margin of 96.09% and a negative return on equity of 17.37%. The business had revenue of $32.81 million during the quarter, compared to analysts’ expectations of $39.42 million. Arrowhead Pharmaceuticals’s quarterly revenue was up 39.4% compared to the same quarter last year. On average, analysts predict that Arrowhead Pharmaceuticals, Inc. will post -0.04 earnings per share for the current year.
Arrowhead Pharmaceuticals Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma.
Featured Story: How to build a Fibonacci channel
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.